Review of the crystallized structures of the SARS-CoV-2 papain-like protease

被引:0
|
作者
Qiu, Yue [1 ,3 ,4 ]
Jiang, Hua-Juan [1 ]
Yang, Yu-Shun [1 ]
Hu, Xiao-Qin [1 ,2 ]
Zeng, Xue-Wen [1 ]
机构
[1] Jinhua Adv Res Inst, Jinhua 321019, Peoples R China
[2] Zhejiang Normal Univ, Xingzhi Coll, Lanxi 321100, Peoples R China
[3] Macau Univ Sci & Technol, Taipa 999078, Macao, Peoples R China
[4] Macau Univ Sci & Technol, Dr Nehers Biophys Lab Innovat Drug Discovery, State Key Lab Qual Res Chinese Med, Taipa, Macao, Peoples R China
关键词
COVID-19; Papain-like protease; Coronavirus; SARS-CoV-2; PLpro; Inhibitors; Protein Data Bank; RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR-DYNAMICS SIMULATIONS; SLOW-BINDING INHIBITORS; SARS-COV; BIOLOGICAL EVALUATION; SELECTIVE INHIBITORS; VIRUS; IDENTIFICATION; DESIGN; DOMAIN;
D O I
10.1016/j.molstruc.2025.141730
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
In late 2019, a new CoV have caused the outbreak of deadly respiratory disease, the COVID-19 pandemic. Due to the profound impact of these viral outbreaks on public health and the economy, while several effective vaccines and antiviral drugs for SARS-CoV-2 are now available, the continuous emergence of variants highlights the ongoing need for therapeutic innovation and structural studies. The SARS-CoV-2 papain-like protease (PLpro) plays a vital role in viral replication and host immune evasion, making it a key target for therapeutic intervention. However, a series of SARS-CoV-2 PLpro structures have been published from April 1, 2020 to December 31, 2024 and it is found that a lot of literature knowledge is scattered. This article reviews the structures of these crystallized proteins, categorizes and summarizes key structural features, and compiles a wide range of existing inhibitors for preliminary analysis. Most importantly, it sorts out some known and potential cryptic binding sites, analyzing their strengths and weaknesses in conjunction with relevant literature. Through this review, we aim to provide valuable insights for future research on PLpro.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Crystal structure of SARS-CoV-2 papain-like protease
    Gao, Xiaopan
    Qin, Bo
    Chen, Pu
    Zhu, Kaixiang
    Hou, Pengjiao
    Wojdyla, Justyna Aleksandra
    Wang, Meitian
    Cui, Sheng
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (01) : 237 - 245
  • [2] The SARS-CoV-2 SSHHPS Recognized by the Papain-like Protease
    Reynolds, Nathanael D.
    Aceves, Nathalie M.
    Liu, Jinny L.
    Compton, Jaimee R.
    Leary, Dagmar H.
    Freitas, Brendan T.
    Pegan, Scott D.
    Doctor, Katarina Z.
    Wu, Fred Y.
    Hu, Xin
    Legler, Patricia M.
    ACS INFECTIOUS DISEASES, 2021, 7 (06): : 1483 - 1502
  • [3] Crystal structure of SARS-CoV-2 papain-like protease
    Xiaopan Gao
    Bo Qin
    Pu Chen
    Kaixiang Zhu
    Pengjiao Hou
    Justyna Aleksandra Wojdyla
    Meitian Wang
    Sheng Cui
    Acta Pharmaceutica Sinica B, 2021, 11 (01) : 237 - 245
  • [4] Drug Repurposing for the SARS-CoV-2 Papain-Like Protease
    Cho, Chia-Chuan
    Li, Shuhua G.
    Lalonde, Tyler J.
    Yang, Kai S.
    Yu, Ge
    Qiao, Yuchen
    Xu, Shiqing
    Ray Liu, Wenshe
    CHEMMEDCHEM, 2022, 17 (01)
  • [5] A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease
    Alessandra S. Rieder
    Bruna F. Deniz
    Carlos Alexandre Netto
    Angela T.S. Wyse
    Neurotoxicity Research, 2022, 40 : 1553 - 1569
  • [6] Targeting SARS-CoV-2 papain-like protease in the postvaccine era
    Ton, Anh-Tien
    Pandey, Mohit
    Smith, Jason R.
    Ban, Fuqiang
    Fernandez, Michael
    Cherkasov, Artem
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (11) : 906 - 919
  • [7] Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
    Klemm, Theresa
    Ebert, Gregor
    Calleja, Dale J.
    Allison, Cody C.
    Richardson, Lachlan W.
    Bernardini, Jonathan P.
    Lu, Bernadine G. C.
    Kuchel, Nathan W.
    Grohmann, Christoph
    Shibata, Yuri
    Gan, Zhong Yan
    Cooney, James P.
    Doerflinger, Marcel
    Au, Amanda E.
    Blackmore, Timothy R.
    van der Heden van Noort, Gerbrand J.
    Geurink, Paul P.
    Ovaa, Huib
    Newman, Janet
    Riboldi-Tunnicliffe, Alan
    Czabotar, Peter E.
    Mitchell, Jeffrey P.
    Feltham, Rebecca
    Lechtenberg, Bernhard C.
    Lowes, Kym N.
    Dewson, Grant
    Pellegrini, Marc
    Lessene, Guillaume
    Komander, David
    EMBO JOURNAL, 2020, 39 (18):
  • [8] A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease
    Rieder, Alessandra S.
    Deniz, Bruna F.
    Netto, Carlos Alexandre
    Wyse, Angela T. S.
    NEUROTOXICITY RESEARCH, 2022, 40 (05) : 1553 - 1569
  • [9] Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro
    Kiba, Yuka
    Tanikawa, Takashi
    Kitamura, Masashi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (05) : 965 - 966
  • [10] Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
    Ma, Chunlong
    Wang, Jun
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, 5 (02) : 102 - 109